Icon’s business resilience, underlined by its large customer base and minimal dependence on fluctuating biotech capital markets, justifies the Outperform rating and optimistic price target set ...
A favorable global environment has allowed them to lock in longer-term funding and improve debt structures. Emerging market countries, though still a small share of overall capital flows, have seen ...